Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03028974 · ClinicalTrials.gov registry record · Phase 4

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

A Phase 4 study, sponsored by Stanford University.

Completed
Registry status
Phase 4
Development phase
77
Enrollment target

NCT03028974: Completed Phase 4 study, sponsored by Stanford University.

NCT03028974 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 77 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03028974, a Phase 4 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 4
Development phase
77 participants
Enrollment target

Study Summary

The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.

Interventions

  • BIOLOGICAL Fluzone®
  • BIOLOGICAL FluMist®

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2014-09-17
Est. Completion 2017-11-20
Phase Phase 4
Stanford University

1,744 total trials

What the finished NCT03028974 record still lists

NCT03028974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which Fluzone® is the first listed.

NCT03028974 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03028974 about?

NCT03028974 is a clinical study titled "Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)". The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.

What is the current status of trial NCT03028974?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2014-09-17. Estimated completion is 2017-11-20.

What interventions are being tested in trial NCT03028974?

The interventions under investigation include: Fluzone® (BIOLOGICAL), FluMist® (BIOLOGICAL).

Who is sponsoring clinical trial NCT03028974?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03028974's enrollment target sits among peer trials

77 989th of 2000 higher than 1,007 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02127398 · 77 participants · Phase 2

    Stool Transplants to Treat Refractory Clostridium Difficile Colitis

  • NCT04159103 · 77 participants · Phase 1

    Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • NCT04683003 · 77 participants · Phase 3

    A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

  • NCT05004116 · 77 participants · Phase 1

    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03028974, the US trial registry maintained by the National Library of Medicine. NCT03028974 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.